Research toward the development of beta-TCP as a novel vaccine adjuvant.
| Project/Area Number |
26350524
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biomaterial science and engineering
|
|---|
| Research Institution | Shizuoka Cancer Center Research Institute |
|---|
Principal Investigator |
Maruyama Kouji 静岡県立静岡がんセンター(研究所), その他部局等, 研究員 (20311417)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
ISHII Hidee 静岡県立静岡がんセンター研究所, 実験動物管理室, 研究員 (60571213)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | β-TCP / 免疫賦活 / マクロファージ / 樹状細胞 / インフラマソーム / ワクチン・アジュバント / 癌ワクチン |
|---|
| Outline of Final Research Achievements |
Beta-tricalcium phosphate (β-TCP) has a reliable long carrier as a bone substituent used in the clinic. In the present study, we focused on the immuno-stimulating potential of β-TCP, and carried out research toward the development of β-TCP as a novel vaccine adjuvant, and obtained the following findings; 1) β-TCP activates and induces maturation of macrophages (MΦ) and dendritic cells (DC). 2) β-TCP activates inflammasomes in MΦ and DC in the presence of ligands for Toll-like receptors (TLR). 3) β-TCP and TLR ligand synergistically enhances antitumor effect of a cancer vaccine in a mouse tumor model. These findings indicate that the potential of β-TCP as a novel vaccine adjuvant.
|
Report
(3 results)
Research Products
(1 results)
